Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Annals of the Rheumatic Diseases

Volumn 75, Issue 4, 2016, Pages 709-714

  Sokolove, Jeremy ^a   Schiff, Michael ^b   Fleischmann, Roy ^c   Weinblatt, Michael E ^d   Connolly, Sean E ^e   Johnsen, Alyssa ^e   Zhu, Jin ^e   Maldonado, Michael A ^e   Patel, Salil ^e   Robinson, William H ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE 2 ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; METHOTREXATE; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; IMMUNOGLOBULIN G;

ADULT; ANTIBODY DETECTION; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISABILITY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; EXPLORATORY RESEARCH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; AGED; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; IMMUNOLOGY; MIDDLE AGED; PROGNOSIS; SINGLE BLIND PROCEDURE; SUBCUTANEOUS DRUG ADMINISTRATION; VERY ELDERLY; YOUNG ADULT;

ABATACEPT; ADALIMUMAB; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84941662740     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207942     Document Type: Article

References (20)

1. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) 2006;45:20-5.
2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
3. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.
4. Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One 2012;7:e35296.
5. Willemze A, Trouw LA, Toes RE, et al. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144-52.
6. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
7. Ursum J, Bos WH, van Dillen N, et al. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12:R8.
8. Lv Q, Yin Y, Li X, et al. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFa agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS ONE 2014;9:e89442.
9. Pruijn GJ, Wiik A, van Venrooij WJ. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010;12:203.
10. Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94.
11. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38.
12. Pomirleanu C, Ancuta C, Miu S, et al. A predictive model for remission and low disease activity in patients with established rheumatoid arthritis receiving TNF blockers. Clin Rheumatol 2013;32:665-70.
13. Fisher BA, Plant D, Lundberg K, et al. Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis. J Rheumatol 2012;39:929-32.
14. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009;68:69-74.
15. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.
16. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
17. Gottenberg JE, Ravaud P, Bardin T, et al. Positivity for RF/anti-CCP is associated with a better response to abatacept: data from the "Orencia and Rheumatoid Arthritis" (ORA) registry. Ann Rheum Dis 2011;70(Suppl 3):74.
18. Gottenberg JE, Neto D, Gomez-Reino J, et al. Positivity for rheumatoid factor and anti-cyclic citrullinated peptide is associated with better drug retention of abatacept: data from a pan-European analysis of RA registries. Ann Rheum Dis 2014;73(Suppl 2):502.
19. Fujii T, Sekiguchi M, Matsui K, et al. Very high titer of anti-citrullinated protein antibodies is associated with the achievement of clinical remission by abatacept in biologic-naïve patients with rheumatoid arthritis (the ABROAD study). Ann Rheum Dis 2013;72(Suppl 3):889.
20. Nüßlein H, Alten R, Galeazzi M, et al. Two-year retention and effectiveness of IV abatacept in real-life setting: results from the ACTION study. Ann Rheum Dis 2014;73(Suppl 2):500.